Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies (ID3828)

£8.2M GBP

Funder	National Institute for Health Research
Recipient Organization	University of Southampton
Country	United Kingdom
Start Date	Apr 21, 2021
End Date	Oct 05, 2021
Duration	167 days
Number of Grantees	1
Roles	Award Holder
Data Source	Europe PMC
Grant ID	`NIHR134065`

Grant Description

To appraise the clinical and cost effectiveness of tucatinib with trastuzumab and capecitabine within its marketing authorisation for treating HER2-positive locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies.